Literature DB >> 28366764

In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.

Chaoran Yin1, Ting Zhang1, Xiying Qu2, Yonggang Zhang1, Raj Putatunda1, Xiao Xiao1, Fang Li1, Weidong Xiao3, Huaqing Zhao4, Shen Dai1, Xuebin Qin1, Xianming Mo5, Won-Bin Young6, Kamel Khalili7, Wenhui Hu8.   

Abstract

CRISPR-associated protein 9 (Cas9)-mediated genome editing provides a promising cure for HIV-1/AIDS; however, gene delivery efficiency in vivo remains an obstacle to overcome. Here, we demonstrate the feasibility and efficiency of excising the HIV-1 provirus in three different animal models using an all-in-one adeno-associated virus (AAV) vector to deliver multiplex single-guide RNAs (sgRNAs) plus Staphylococcus aureus Cas9 (saCas9). The quadruplex sgRNAs/saCas9 vector outperformed the duplex vector in excising the integrated HIV-1 genome in cultured neural stem/progenitor cells from HIV-1 Tg26 transgenic mice. Intravenously injected quadruplex sgRNAs/saCas9 AAV-DJ/8 excised HIV-1 proviral DNA and significantly reduced viral RNA expression in several organs/tissues of Tg26 mice. In EcoHIV acutely infected mice, intravenously injected quadruplex sgRNAs/saCas9 AAV-DJ/8 reduced systemic EcoHIV infection, as determined by live bioluminescence imaging. Additionally, this quadruplex vector induced efficient proviral excision, as determined by PCR genotyping in the liver, lungs, brain, and spleen. Finally, in humanized bone marrow/liver/thymus (BLT) mice with chronic HIV-1 infection, successful proviral excision was detected by PCR genotyping in the spleen, lungs, heart, colon, and brain after a single intravenous injection of quadruplex sgRNAs/saCas9 AAV-DJ/8. In conclusion, in vivo excision of HIV-1 proviral DNA by sgRNAs/saCas9 in solid tissues/organs can be achieved via AAV delivery, a significant step toward human clinical trials.
Copyright © 2017 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; Cas9; HIV; Tg26 mice; animal models; gRNA; gene therapy; genome editing; humanized BLT mice; viral latency

Mesh:

Substances:

Year:  2017        PMID: 28366764      PMCID: PMC5417847          DOI: 10.1016/j.ymthe.2017.03.012

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  85 in total

1.  Rational design of a split-Cas9 enzyme complex.

Authors:  Addison V Wright; Samuel H Sternberg; David W Taylor; Brett T Staahl; Jorge A Bardales; Jack E Kornfeld; Jennifer A Doudna
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

2.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles.

Authors:  Ming Wang; John A Zuris; Fantao Meng; Holly Rees; Shuo Sun; Pu Deng; Yong Han; Xue Gao; Dimitra Pouli; Qi Wu; Irene Georgakoudi; David R Liu; Qiaobing Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

3.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Authors:  Zhen Wang; Qinghua Pan; Patrick Gendron; Weijun Zhu; Fei Guo; Shan Cen; Mark A Wainberg; Chen Liang
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

4.  HIV-1 alters neural and glial progenitor cell dynamics in the central nervous system: coordinated response to opiates during maturation.

Authors:  Yun Kyung Hahn; Elizabeth M Podhaizer; Kurt F Hauser; Pamela E Knapp
Journal:  Glia       Date:  2012-08-02       Impact factor: 7.452

5.  Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells.

Authors:  Lior Nissim; Samuel D Perli; Alexandra Fridkin; Pablo Perez-Pinera; Timothy K Lu
Journal:  Mol Cell       Date:  2014-05-15       Impact factor: 17.970

6.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

7.  Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX.

Authors:  Xin Yu; Xiquan Liang; Huimin Xie; Shantanu Kumar; Namritha Ravinder; Jason Potter; Xavier de Mollerat du Jeu; Jonathan D Chesnut
Journal:  Biotechnol Lett       Date:  2016-02-18       Impact factor: 2.461

8.  Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq.

Authors:  Daesik Kim; Sojung Kim; Sunghyun Kim; Jeongbin Park; Jin-Soo Kim
Journal:  Genome Res       Date:  2016-01-19       Impact factor: 9.043

9.  Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity.

Authors:  Duy P Nguyen; Yuichiro Miyaoka; Luke A Gilbert; Steven J Mayerl; Brian H Lee; Jonathan S Weissman; Bruce R Conklin; James A Wells
Journal:  Nat Commun       Date:  2016-07-01       Impact factor: 14.919

10.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.

Authors:  Gang Wang; Na Zhao; Ben Berkhout; Atze T Das
Journal:  Mol Ther       Date:  2016-01-22       Impact factor: 11.454

View more
  103 in total

1.  A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness.

Authors:  K E Yoder
Journal:  Acta Virol       Date:  2019       Impact factor: 1.162

Review 2.  The multifaceted nature of HIV latency.

Authors:  Caroline Dufour; Pierre Gantner; Rémi Fromentin; Nicolas Chomont
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 3.  Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.

Authors:  Yu-Fan Chuang; Andrew J Phipps; Fan-Li Lin; Valerie Hecht; Alex W Hewitt; Peng-Yuan Wang; Guei-Sheung Liu
Journal:  Cell Mol Life Sci       Date:  2021-01-03       Impact factor: 9.261

4.  Excision of Latent HIV-1 from Infected Cells In Vivo: An Important Step Forward.

Authors:  Harshana S De Silva Feelixge; Keith R Jerome
Journal:  Mol Ther       Date:  2017-04-24       Impact factor: 11.454

5.  HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.

Authors:  Zhen Wang; Wenzhou Wang; Ya Cheng Cui; Qinghua Pan; Weijun Zhu; Patrick Gendron; Fei Guo; Shan Cen; Michael Witcher; Chen Liang
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

6.  The fourth annual BRDS on genome editing and silencing for precision medicines.

Authors:  Amit Kumar Chaudhary; Rajan Sharma Bhattarai; Ram I Mahato
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

Review 7.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

8.  A directed evolution approach to select for novel Adeno-associated virus capsids on an HIV-1 producer T cell line.

Authors:  Dawn P Wooley; Priyanka Sharma; John R Weinstein; Poornima Kotha Lakshmi Narayan; David V Schaffer; Katherine J D A Excoffon
Journal:  J Virol Methods       Date:  2017-09-14       Impact factor: 2.014

9.  Combinatorial CRISPR-Cas9 and RNA Interference Attack on HIV-1 DNA and RNA Can Lead to Cross-Resistance.

Authors:  Na Zhao; Gang Wang; Atze T Das; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells.

Authors:  George N Llewellyn; Eduardo Seclén; Stephen Wietgrefe; Siyu Liu; Morgan Chateau; Hua Pei; Katherine Perkey; Matthew D Marsden; Sarah J Hinkley; David E Paschon; Michael C Holmes; Jerome A Zack; Stan G Louie; Ashley T Haase; Paula M Cannon
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.